Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results

This article was originally published in The Pink Sheet Daily

Executive Summary

The drug maker also reports rising sales for its dyslipidemia franchise.

You may also be interested in...



New Zealand's PHARMAC Gains $41 Million In Funding; Adds Sprycel And Humira For Reimbursement

PERTH, Australia - New Zealand's Pharmaceutical Management Agency's 2009/2010 budget saw a $41 million increase, bringing the total agency budget to $694 million, with $10 million of the new funds transferred from New Zealand District Health Board budgets

J&J's Intravenous Remicade Grows Despite Tough Times

Implications for anti-TNFs Humira and Enbrel, which tumbled in the first quarter, are unclear.

AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix

AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.

Related Content

Topics

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel